Alana Bradbury
Nurse Practitioner · St George, UTNPI 1982202446
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 293 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 40 manufacturers reported payments, led by AbbVie at 30.7% of the total. 2025 is the largest year on record at $1,395, more than ten times the $136 reported in 2021. Among nurse practitioner clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 293 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lilly USA, LLC$401
- AstraZeneca$361
- Pfizer$239
- Teva Pharmaceuticals USA, Inc.$186
- Boston Scientific$167
- plus $2K from 34 others
What the payments were for
- Food & beverage$4,911100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 96 | $1,512 |
| Lilly USA, LLC | 33 | $401 |
| AstraZeneca | 20 | $361 |
| Pfizer | 14 | $239 |
| Teva Pharmaceuticals USA, Inc. | 8 | $186 |
| Boston Scientific | 8 | $167 |
| Bayer | 10 | $160 |
| Aimmune Therapeutics, Inc. | 9 | $150 |
| Novo Nordisk | 8 | $135 |
| Amgen | 8 | $134 |
| Lundbeck LLC | 7 | $127 |
| Johnson & Johnson | 6 | $114 |
| Boehringer Ingelheim | 6 | $111 |
| Novartis | 5 | $100 |
| Nestle Healthcare Nutrition Inc. | 5 | $100 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $95 |
| Otsuka America Pharmaceutical, Inc. | 4 | $80 |
| GSK | 4 | $66 |
| Phathom Pharmaceuticals, Inc. | 3 | $55 |
| Harmony Biosciences LLC | 2 | $53 |
| Alfasigma USA, Inc. | 2 | $47 |
| Axsome Therapeutics, Inc. | 2 | $47 |
| Exact Sciences | 3 | $46 |
| Sanofi-aventis U.S. LLC | 2 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Neurocrine Biosciences, Inc. | 2 | $40 |
| Alkermes, Inc. | 2 | $34 |
| Vanda Pharmaceuticals Inc. | 1 | $33 |
| Jazz Pharmaceuticals Inc. | 2 | $32 |
| Merck | 2 | $31 |
| Organon | 2 | $28 |
| Corium, LLC | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Acella Pharmaceuticals, LLC | 1 | $17 |
| Medtronic | 1 | $17 |
| Digestive Care, Inc. | 1 | $15 |
| Neurelis, Inc. | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$110
How this compares
$4,924 in reported general payments places this provider in the 95th percentile of 979 nurse practitioner providers in Utah.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 61 | $70,899 |
| EliquisApixaban | 36 | $30,286 |
| JanuviaSitagliptin Phosphate | 20 | $17,325 |
| JardianceEmpagliflozin | 16 | $13,080 |
| TrintellixVortioxetine Hydrobromide | 28 | $11,697 |
| FarxigaDapagliflozin Propanediol | 18 | $9,229 |
| XareltoRivaroxaban | 13 | $7,190 |
| Omeprazole | 65 | $1,176 |
| Levothyroxine Sodium | 106 | $984 |
| Methylprednisolone | 105 | $879 |
| Atomoxetine Hcl | 15 | $833 |
| Naltrexone Hcl | 14 | $813 |
| WaterWater For Irrigation,sterile | 11 | $720 |
| ValacyclovirValacyclovir Hcl | 13 | $687 |
| Rosuvastatin Calcium | 55 | $670 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $135 | $70,89961 claims |
| PfizerEliquis | $239 | $30,28636 claims |
| MerckJanuvia | $31 | $17,32520 claims |
| Boehringer IngelheimJardiance | $111 | $13,08016 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $41 | $11,69728 claims |
| AstraZenecaFarxiga | $361 | $9,22918 claims |
| Johnson & JohnsonXarelto | $114 | $7,19013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 979 nurse practitioner providers in Utah.
Other nurse practitioner in St George
- Brookanne MickelsonSt George$5K
- David GambleAmerican Fork$836K
- Julia BattenSalt Lake City$223K
- Stacie EganOgden$170K
- Traci AndreasonLehi$161K
- Geoffrey OsmondDraper$62K
- Trenton GraySouth Salt Lake$40K
- Kelsey FurrWest Jordan$21K
- Merin KinikiniSalt Lake City$19K
- Lynn LarsenOgden$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.